updated landing page with publication info

Covid19EstimationHydroxychloroquine/ui.R

@@ -25,7 +25,7 @@ shinyUI(
             tabsetPanel(id = "mainTabsetPanel",
                         tabPanel("About",
                                  HTML("<br/>"),
-                                 div(p("The Observational Health Data Sciences and Informatics (OHDSI) international community hosted a COVID-19 virtual study-a-thon over March 26-29, 2020 to collaboratively generate evidence to inform healthcare decision-making in response to the current global pandemic. The preliminary research results on this web-based application are from a retrospective, real-world, observational study in support of this activity and will subsequently be submitted to a peer-reviewed, scientific journal. During manuscript development and the subsequent review period, these results are considered under embargo and should not be disclosed without explicit permission and consent from the authors."), style="border: 1px solid black; padding: 5px;"),
+                                 div(p("The Observational Health Data Sciences and Informatics (OHDSI) international community hosted a COVID-19 virtual study-a-thon over March 26-29, 2020 to collaboratively generate evidence to inform healthcare decision-making in response to the current global pandemic. The results on this web-based application are from a retrospective, real-world, observational study that assessed the risks of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis. It is a supplement to the manuscript published in Lancet Rheumatology."), style="border: 1px solid black; padding: 5px;"),
                                  HTML("<br/>"),
                                  HTML("<p>Below is the abstract of the manuscript that summarizes the findings:</p>"),
                                  HTML("<p><strong>Background:</strong> Hydroxychloroquine, a drug commonly used in the treatment of rheumatoid arthritis, has received much negative publicity for adverse events associated with its authorisation for emergency use to treat patients with COVID-19 pneumonia. We studied the safety of hydroxychloroquine, alone and in combination with azithromycin, to determine the risk associated with its use in routine care in the patients with rheumatoid arthritis.</strong></p>"),
@@ -35,6 +35,7 @@ shinyUI(
                                  HTML("<br/>"),
                                  HTML("<p>Below are links for study-related artifacts that have been made available as part of this study:</p>"),
                                  HTML("<ul>"),
+                                 HTML("<li>The full manuscript is available at:  <a href=\"https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30276-9/fulltext\">https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30276-9/fulltext</a></li>"),
                                  HTML("<li>This study was registered at ENCePP (EU PAS Register number EUPAS34497): <a href=\"http://www.encepp.eu/encepp/viewResource.htm?id=34498\">http://www.encepp.eu/encepp/viewResource.htm?id=34498</a></li>"),
                                  HTML("<li>The full study protocol is available at:  <a href=\"https://github.com/ohdsi-studies/Covid19EstimationHydroxychloroquine/tree/master/documents\">https://github.com/ohdsi-studies/Covid19EstimationHydroxychloroquine/tree/master/documents</a></li>"),
                                  HTML("<li>The full source code for the study is available at: <a href=\"https://github.com/ohdsi-studies/Covid19EstimationHydroxychloroquine\">https://github.com/ohdsi-studies/Covid19EstimationHydroxychloroquine</a></li>"),